Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,946 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K. Chapman MA, et al. Among authors: smith p. Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4. Blood. 2018. PMID: 30181174 Free PMC article. Clinical Trial.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Cohen OC, Counsell N, Rabin N, Popat R, Owen RG, Popova B, Schofield O, Clifton-Hadley L, Lyons-Lewis J, Rawstron A, Spence C, de Tute RM, Hughes D, Moore S, Smith P, Yong KL. Cohen OC, et al. Among authors: smith p. Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20. Br J Haematol. 2019. PMID: 30460696 Free article. No abstract available.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Popat R, Counsell N, de Tute R, De-Silva D, Phillips EH, Cavenagh JD, Adedayo T, Braganca N, Roddie C, Streetly M, Schey S, Koh MBC, Crowe J, Morris TC, Cook G, Smith P, Clifton-Hadley L, Rabin N, Owen R, Yong K; PADIMAC investigators. Popat R, et al. Among authors: smith p. Br J Haematol. 2021 May;193(3):e19-e22. doi: 10.1111/bjh.17391. Epub 2021 Mar 14. Br J Haematol. 2021. PMID: 33715154 Clinical Trial. No abstract available.
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
Gohil SH, Maciocia N, Patrick P, Roberts T, Counsell N, Smith P, Clifton-Hadley L, Cwynarski K, Pettitt A, Nathwani AC. Gohil SH, et al. Among authors: smith p. Leuk Lymphoma. 2018 Jul;59(7):1730-1733. doi: 10.1080/10428194.2017.1399311. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29164978 No abstract available.
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Mikhaeel NG, Cunningham D, Counsell N, McMillan A, Radford JA, Ardeshna KM, Lawrie A, Smith P, Clifton-Hadley L, O'Doherty MJ, Barrington SF. Mikhaeel NG, et al. Among authors: smith p. Br J Haematol. 2021 Feb;192(3):504-513. doi: 10.1111/bjh.16875. Epub 2020 Jul 4. Br J Haematol. 2021. PMID: 32621535 Free article. Clinical Trial.
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S. Radford J, et al. Among authors: smith p. N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648. N Engl J Med. 2015. PMID: 25901426 Free article. Clinical Trial.
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW. Barrington SF, et al. Among authors: smith p. Blood. 2016 Mar 24;127(12):1531-8. doi: 10.1182/blood-2015-11-679407. Epub 2016 Jan 8. Blood. 2016. PMID: 26747247 Free article.
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Gleeson M, Counsell N, Cunningham D, Lawrie A, Clifton-Hadley L, Hawkes E, McMillan A, Ardeshna KM, Burton C, Chadwick N, Gambell J, Smith P, Mouncey P, Pocock C, Radford J, Davies J, Turner D, Kruger A, Johnson P, Linch D. Gleeson M, et al. Among authors: smith p. Br J Haematol. 2021 Mar;192(6):1015-1019. doi: 10.1111/bjh.16691. Epub 2020 May 20. Br J Haematol. 2021. PMID: 32436212 Free article. Clinical Trial.
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D. Fields PA, et al. Among authors: smith p. J Clin Oncol. 2014 Feb 1;32(4):282-7. doi: 10.1200/JCO.2013.49.7586. Epub 2013 Nov 12. J Clin Oncol. 2014. PMID: 24220559 Clinical Trial.
12,946 results
You have reached the last available page of results. Please see the User Guide for more information.